Successful Erythropoietin Therapy after Alemtuzumab and Cyclosporin a Treatment for Epoetin-Induced Pure Red Cell Aplasia.
- Author:
Hyemin PARK
1
;
Jaeuk IM
;
Juhwan PARK
;
Enhye KIM
;
Honggil JUN
;
Jae Hoo PARK
;
Hawk KIM
Author Information
1. Division of Hematology and Hematological Malignancies, Department of Internal Medicine, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea. kimhawkmd@gmail.com
- Publication Type:Case Report
- Keywords:
Alemtuzumab;
Cyclosporin A;
Pure red cell aplasia
- MeSH:
Adult;
Antibodies, Monoclonal, Humanized;
Cyclosporine;
Erythropoietin;
Humans;
Red-Cell Aplasia, Pure
- From:Korean Journal of Medicine
2013;85(2):214-217
- CountryRepublic of Korea
- Language:English
-
Abstract:
Pure red cell aplasia (PRCA) in adults is usually idiopathic, although some underlying conditions can cause PRCA. Immunosuppressive therapy (IST) is used to treat PRCA, but IST has side effects and may fail. The anti-CD52 monoclonal antibody alemtuzumab (ALM) was recently used to successfully treat therapy-resistant PRCA. We herein report successful treatment of secondary PRCA after erythropoietin therapy using ALM and cyclosporin A (CsA) in one patient. The total dose of ALM was 60 mg over 3 days (10, 20, and 30 mg, respectively) plus CsA for at least 6 months. The patient achieved a complete response 18 months after ALM-CsA treatment and his treatment could be changed to a different erythropoietin-stimulating agent.
